Suppr超能文献

利用新型融合毒素-白喉毒素/HN-1 靶向头颈部鳞状细胞癌。

Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.

机构信息

Stem Cell & Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, #201, Bhupat and Jyoti Mehta School of Biosciences Building, Chennai, 600036, India.

出版信息

Mol Biol Rep. 2011 Feb;38(2):1389-97. doi: 10.1007/s11033-010-0242-8. Epub 2010 Aug 1.

Abstract

The current treatment strategies, chemotherapy and radiation therapy being used for the management of cancer are deficient in targeted approach leading to treatment related toxicities and relapse. Contrarily, fusion toxins exhibit remarkable tumor specificity thus emerging as an alternative therapy for the treatment of cancer. Diphtheria toxin-HN-1 peptide (DT/HN-1) is a fusion toxin designed to target the head and neck squamous cell carcinoma (HNSCC). The aim of this study was to construct, characterize, and evaluate the cytotoxicity and specificity of DT/HN-1 fusion toxin against the HNSCC cells. The purified DT/HN-1 fusion toxin was characterized by SDS-PAGE and western blotting. Refolding of purified fusion toxins was monitored by fluorescence spectra and circular dichroism spectra. The activity of DT/HN-1 fusion toxin was demonstrated on various HNSCC cell lines by cell viability assay, cell proliferation assay, protein synthesis inhibition assay, apoptosis and cell cycle analysis. The fusion toxin DT/HN-1 demonstrated remarkably high degree of cytotoxicity specific to the HNSCC cells. The IC(50) of DT/HN-1 fusion toxin was ~1 to 5 nM in all the three HNSCC cell lines. The percentage apoptotic cells in DT/HN-1 treated UMB-SCC-745 cells are 16% compared to 4% in untreated. To further demonstrate the specific toxicity of DT/HN-1 fusion toxin towards the HNSCC cells we constructed, characterized and evaluated the efficacy of DT protein. The DT protein coding for only a fragment of diphtheria toxin without its native receptor binding domain failed to exhibit any cytotoxicity on all the cell lines used in this study thus establishing the importance of a ligand in achieving targeted toxicity. To evaluate the translocation ability of HN-1 peptide, an additional construct DTΔT/HN-1 was constructed, characterized and evaluated for its cytotoxic activity. The fusion toxin DTΔT/HN-1 deficient of the translocation domain of diphtheria toxin showed no cytotoxicity on all the cell lines clearly indicating the inability of HN-1 peptide to translocate catalytic domain of the toxin into the cytosol.

摘要

目前用于癌症治疗的策略,包括化疗和放疗,在靶向治疗方面存在不足,导致治疗相关的毒性和复发。相比之下,融合毒素表现出显著的肿瘤特异性,因此成为癌症治疗的另一种选择。白喉毒素-HN-1 肽(DT/HN-1)是一种设计用于靶向头颈部鳞状细胞癌(HNSCC)的融合毒素。本研究旨在构建、表征和评估 DT/HN-1 融合毒素对 HNSCC 细胞的细胞毒性和特异性。纯化的 DT/HN-1 融合毒素通过 SDS-PAGE 和 Western blot 进行表征。通过荧光光谱和圆二色性光谱监测纯化融合毒素的重折叠。通过细胞活力测定、细胞增殖测定、蛋白质合成抑制测定、凋亡和细胞周期分析,在各种 HNSCC 细胞系上研究了 DT/HN-1 融合毒素的活性。融合毒素 DT/HN-1 对 HNSCC 细胞表现出显著的高细胞毒性。在所有三种 HNSCC 细胞系中,DT/HN-1 融合毒素的 IC50 约为 1 至 5 nM。与未经处理的细胞相比,DT/HN-1 处理的 UMB-SCC-745 细胞中的凋亡细胞百分比为 16%。为了进一步证明 DT/HN-1 融合毒素对我们构建的 HNSCC 细胞的特异性毒性,我们构建、表征和评估了 DT 蛋白的功效。编码白喉毒素仅片段而没有其天然受体结合结构域的 DT 蛋白未能在本研究中使用的所有细胞系上显示出任何细胞毒性,从而证明了配体在实现靶向毒性方面的重要性。为了评估 HN-1 肽的易位能力,构建了另一个构建体 DTΔT/HN-1,对其细胞毒性活性进行了表征和评估。缺乏白喉毒素易位结构域的融合毒素 DTΔT/HN-1 在所有细胞系上均无细胞毒性,这清楚地表明 HN-1 肽不能将毒素的催化结构域易位到细胞质中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验